Glucocorticoids safety administration in multiple sclerosis treatment: A focus on physicians’ adherence to avoid side effect
More details
Hide details
Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine
Olena Volodymyrivna Gerasymenko   

Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Pushkinska 27, Kharkiv 61002, Ukraine. Tel.: +38066 711 85 70.
Online publication date: 2018-03-07
Publication date: 2019-11-17
Submission date: 2017-08-18
Acceptance date: 2017-10-25
Pol. Ann. Med. 2018;25(1):91–97
The problems of GCs administration safety in MS patients have not been solved yet because of their side effects, absence of the alternative treatment for acute relapse onset and its rapid progression.

To analyze clinical and pharmaceutical aspects of GCs rational use in practical treatment of MS patients throughout studying of physicians’ adherence to follow the recommendation of avoiding their side effects.

Material and methods:
This is a retrospective study of 50 randomized MS case histories.

Results and discussion:
Twenty two (44 %) of MS patients had clinical and anamnestic risk factors for GCs use. However, GCs have been prescribed in 27 cases (54 %) of current hospitalization, in 26 (52 %) of patients’ anamnesis, and 38 (76 %) of patients, totally. During a hospital stage 44.44 % received pulse therapy, 59.26 % - oral GCs and 11.11 % - endolumbal administration. GCs were frequently used in MS onset during current hospitalization and in SPMS in pre-hospital period. Approximately 91 % with EDSS 5-6 were treated with GCs. We have observed possible side effects of GCs in 31.58 % among 38 MS cases treated with CGs, however, the patients have not been properly examined for their estimation. We have discovered that physicians paid more attention to prevention of gastrointestinal side effect of GCs (51.85 %), than osteoporosis. We also found 3 cases (11.11 %) of irrational combinations of GCs with NSAIDs.

GCs are frequently and effectively prescribed to MS patients, their side effects are still under proper control in clinical practice.

Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145–1153.
Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005;11(4):425–432.
Barnes PJ. Therapeutic strategies for allergic diseases. Nature. 1999;402:31–38.
Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522–543.
Moroz V.A. [Local corticosteroids: choice for maximal favor]. Provizor. 2007;9:17–20 [in Russian].
Perico N, Remuzzi G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs. 1997;54(4):533–570.
Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA. 1993;269(16):2110–2112.
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–865.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44(7):1496–1503.<1496::AID-ART271>3.0.CO;2-5.
Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239–248.
Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J. 2004;81(955):302–308.
Vasilovsky VV, Voloshina NP, Negreba TV, Levchenko IL, Chernenk ME, Tkachyova TN. The experience of applying and efficiency of intrathecal introduction of glucocorticoids in progressive courses of multiple sclerosis. Ukranian Neurological J. 2014;1(30):68–74.
Sharrack B, Hughes RA, Morris RW, et al. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. J Neurol Sci. 2000;173(1):73–77.
Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53(4):528–535.
Miura M, Ohki H, Yoshiba S, et al. Adverse effect of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90(10):1096–1097.
White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30(5 Pt 1):768–773.
Cohen-Cymberknon M, Blau H, Shoseyov D, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cystic Fibrosis. 2009;8(4):253–257.
Luo JC, Chang FY, Chen TS, et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol. 2009;68(2):252–259.
Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70(6):956–960.
Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2007;57(1):140–146.
Haugeberg G, Griffithis B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis. 2004;63(8):940–944.
Arslan S, Celiker R, Karabudak R. Cumulative corticosteroid doses and osteoporosis in patients with multiple sclerosis. Turk J Rheumatol. 2010;25(4):191–195.
Canalis E, Maziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis. Clin Ther. 2004;26:1–14.
Miller DM, Weinstock-Guttman B, Béthoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler. 2000;6(4):267–273.
Nos C, Sastre-Garriga J, Borràs C, Tintoré M, Montalban X. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Mult Scler. 2004;10(4):413–416.
Pascual AM, Boscá I, Escutia M, Bernat A, Coret F, Casanova B. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data]. Neurologia. 2008;23(2):73–77 [in Spanish].
Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;(1):CD006264.
Sundahl N, Bridelance J, Libert C, De Bosscher K, Beck IM. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. Pharmacol Therapeut. 2015;152:28–41.
Farooqi AZ, Nasir-ud-Din, Aman R, Qamar T, Aziz S. Corticosteroid use and abuse by medical practitioners for arthritis and related disorders in Pakistan. Br J Rheumatol. 1997;36(1):91–94.
Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA. Impact of multiple sclerosis relapse: The NARCOMS participant perspective. Mult Scler Relat Disord. 2015;4(3):234–240.
Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–740.
Bendtzen K, Hansen PR, Rieneck K, Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003;134(1):151–158.
Kalergis AM, Herrada AA. Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation, which is useful for preventing and/or treating multiple sclerosis. Patent US 20130203719 A1.
Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–1567.
Nowak KM, Papierska L. Prevention and monitoring of the side effects of chronic corticosteroid therapy. Postępy Nauk Medycznych. 2014;27(12):852–859.